Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia  

作　　者：Yanren Peng Danxia Guo Sijie Jiang Hua Zheng 

机构地区：[1]Department of Cardiology,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,China

出　　处：《Chinese Medical Journal》2022年第6期730-731,共2页中华医学杂志（英文版）

摘　　要：To the Editor:The proprotein convertase subtilisin/kexin type 9(PCSK9)-inhibitor,evolocumab,can bind with PCSK9 in plasma and reduce the degradation of the PCSK9-low density lipoprotein(LDL)receptor complex,thereby reducing LDL levels.[1]In clinical practice,PCSK9 inhibitors can reduce low-density lipoprotein cholesterol(LDL-c)significantly and reduce triglycerides(TG)by about 8%to 17%.[2]We used PCSK9 inhibitors to lower blood lipids in three patients with severe hypertriglyceridemia(HTG)and performed whole-exome sequencing(WES)to analyze the genes that may contribute to hyperlipidemia in detail.We have obtained patients'consent forms.We found that PCSK9 inhibitors significantly reduced blood lipid levels,regardless of the presence of HTG mutations.These results provide new evidence for the use of PCSK9 inhibitors in the treatment of patients with severe HTG.

关 键 词：PATIENTS LIPOPROTEIN CONVERT 

分 类 号：R589.2[医药卫生—内分泌]